Edition:
India

Elanco Animal Health Inc (ELAN.N)

ELAN.N on New York Stock Exchange

26.40USD
21 Nov 2019
Change (% chg)

$0.05 (+0.19%)
Prev Close
$26.35
Open
$26.73
Day's High
$27.00
Day's Low
$26.38
Volume
817,223
Avg. Vol
752,036
52-wk High
$35.46
52-wk Low
$25.25

Latest Key Developments (Source: Significant Developments)

Elanco Animal Health Q3 Adjusted Earnings Per Share $0.30 Including Items
Wednesday, 6 Nov 2019 

Elanco Animal Health Inc ::ELANCO ANIMAL HEALTH REPORTS THIRD QUARTER RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.30 INCLUDING ITEMS.Q3 EARNINGS PER SHARE $0.03.Q3 REVENUE $771.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $765.4 MILLION.SEES FY 2019 EARNINGS PER SHARE $0.10 TO $0.18.SEES FY 2019 REVENUE $3.07 BILLION TO $3.085 BILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.26 -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $1.08, REVENUE VIEW $3.10 BILLION -- REFINITIV IBES DATA.INDEPENDENT COMPANY STAND-UP AND EXIT OF TRANSITIONAL SERVICE AGREEMENTS WITH LILLY ARE ON TRACK.SEES 2019 ADJUSTED EPS $1.04 TO $1.08.  Full Article

Elanco Intends To Eliminate Approximately 250 Positions Across Multiple Locations And Functions
Tuesday, 1 Oct 2019 

Sept 30 (Reuters) - Elanco Animal Health Inc ::ELANCO ADVANCES MARGIN EXPANSION JOURNEY WITH BUSINESS RESTRUCTURING.ELANCO ANIMAL HEALTH INC - ACTIONS EXPECTED TO DRIVE AT LEAST $12 MILLION IN SAVINGS IN 2020.ELANCO ANIMAL HEALTH INC - COMPANY IS ANNOUNCING ITS INTENT TO ELIMINATE APPROXIMATELY 250 POSITIONS ACROSS MULTIPLE LOCATIONS AND FUNCTIONS.ELANCO ANIMAL HEALTH INC - COST OF RESTRUCTURING WILL BE APPROXIMATELY $50 MILLION WITH APPROXIMATELY $30 MILLION RELATING TO NON-CASH ASSET WRITE DOWNS.ELANCO ANIMAL HEALTH INC - EXITING RESEARCH AND DEVELOPMENT OPERATIONS IN PRINCE EDWARD ISLAND, CANADA.ELANCO ANIMAL HEALTH INC - CEASING CERTAIN OPERATIONS AT COMPANY'S WUSI, CHINA SITE.ELANCO ANIMAL HEALTH INC - ESTIMATED RESTRUCTURING CHARGE OF $38 MILLION WILL BE INCURRED IN Q3 2019 WITH REMAINING $12 MILLION TO BE INCURRED IN 2020..ELANCO ANIMAL HEALTH INC - STREAMLINING OPERATIONS AT SPEKE, ENGLAND LOCATION..  Full Article

Elanco Animal Health CEO Jeffrey N Simmons Reports Open Market Purchase Of 75,750 Shares At Average Price Of $26.55 On Sept 4
Thursday, 5 Sep 2019 

Sept 5 (Reuters) - Elanco Animal Health Inc ::ELANCO ANIMAL HEALTH CEO JEFFREY N SIMMONS REPORTS OPEN MARKET PURCHASE OF 75,750 SHARES AT AVERAGE PRICE OF $26.55 ON SEPT 4- SEC FILING.  Full Article

Elanco Animal Health - Not Initiating Dividend In Near Term
Tuesday, 20 Aug 2019 

Aug 20 (Reuters) - Elanco Animal Health Inc ::ELANCO ANIMAL HEALTH - NOT INITIATING DIVIDEND IN NEAR TERM.  Full Article

Bayer To Sell Its Animal Health Business Unit To Elanco For $7.6 Bln
Tuesday, 20 Aug 2019 

Aug 20 (Reuters) - Bayer Ag ::BAYER TO SELL ITS ANIMAL HEALTH BUSINESS UNIT TO ELANCO FOR 7.6 BILLION U.S. DOLLARS.DIVESTMENT IS EXPECTED TO BE CONCLUDED IN MID-2020.BAYER INTENDS TO EXIT ITS STAKE IN ELANCO OVER TIME.  Full Article

Elanco Announces Acquisition Of Prevtec Microbia Swine Vaccine Company
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - Elanco Animal Health Inc ::ELANCO ANNOUNCES ACQUISITION OF PREVTEC MICROBIA SWINE VACCINE COMPANY.ELANCO ANIMAL HEALTH INC - ELANCO ACQUIRED COMPANY, INCLUDING INVENTORY AND PIPELINE ASSETS IN AN ALL-CASH DEAL FOR CAD $78.5 MILLION.ELANCO ANIMAL HEALTH - DEAL INCLUDES CONTINGENT PAYMENT OF UP TO C$21.5 MILLION TO FORMER PREVTEC SHAREHOLDERS IN Q1 2022, IF SALES MILESTONES ARE ACHIEVED IN 2021.  Full Article

Elanco Announces Research And Development Collaboration With AgBiome For Swine Nutritional Health Innovation
Thursday, 27 Jun 2019 

June 27 (Reuters) - Elanco Animal Health Inc ::ELANCO ANNOUNCES RESEARCH AND DEVELOPMENT COLLABORATION WITH AGBIOME FOR SWINE NUTRITIONAL HEALTH INNOVATION.ELANCO ANIMAL HEALTH INC - TERMS OF DEAL WERE NOT DISCLOSED..ELANCO ANIMAL HEALTH - GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION WITH AGBIOME TO DEVELOP NUTRITIONAL HEALTH PRODUCTS FOR SWINE.  Full Article

Elanco Animal Health Q1 Adjusted Earnings Per Share $0.25
Thursday, 9 May 2019 

Elanco Animal Health Inc ::ELANCO ANIMAL HEALTH REPORTS FIRST QUARTER RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.25.Q1 EARNINGS PER SHARE $0.09.Q1 REVENUE $731.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $743.5 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.23 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $3.08 BILLION TO $3.14 BILLION.SEES FY 2019 EARNINGS PER SHARE $0.36 TO $0.48.EXPECTED 2019 REVENUE UPDATED TO BE BETWEEN $3.08 BILLION AND $3.14 BILLION DUE TO CHANGES IN FOREIGN EXCHANGE RATE ASSUMPTIONS.FY2019 EARNINGS PER SHARE VIEW $1.08, REVENUE VIEW $3.13 BILLION -- REFINITIV IBES DATA.EXPECTED 2019 CONSTANT CURRENCY REVENUE GROWTH AT 4 TO 6 PERCENT REMAINS UNCHANGED.SEES 2019 EARNINGS PER SHARE $1.02 TO $1.12 ON AN ADJUSTED BASIS.FY2019 EARNINGS PER SHARE VIEW $1.08, REVENUE VIEW $3.13 BILLION -- REFINITIV IBES DATA.  Full Article

Eli Lilly And Co Qtrly Non-GAAP EPS $1.33
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Eli Lilly And Co ::LILLY REPORTS SOLID FIRST-QUARTER 2019 FINANCIAL RESULTS, UPDATES 2019 GUIDANCE TO REFLECT DISPOSITION OF ELANCO ANIMAL HEALTH.SEES FY 2019 EARNINGS PER SHARE $8.57 TO $8.67.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $5.60 TO $5.70.QTRLY EPS REPORTED $4.31.IN Q1 OF 2019, WORLDWIDE REVENUE WAS $5.092 BILLION, AN INCREASE OF 3 PERCENT COMPARED WITH Q1 OF 2018.2019 EPS GUIDANCE UPDATED TO BE IN RANGE OF $8.57 TO $8.67 ON A REPORTED BASIS AND $5.60 TO $5.70 ON A NON-GAAP BASIS.QTRLY EPS - NON-GAAP $1.33.FIRST-QUARTER 2019 WORLDWIDE TRULICITY REVENUE WAS $879.7 MILLION, AN INCREASE OF 30 PERCENT COMPARED WITH Q1 OF 2018.FIRST-QUARTER 2019 EPS ON A REPORTED BASIS INCLUDES GAIN ON SALE ASSOCIATED WITH DISPOSITION OF ELANCO ANIMAL HEALTH.FOR Q1 OF 2019, WORLDWIDE HUMALOG REVENUE DECREASED 8 PERCENT COMPARED WITH Q1 OF 2018, TO $730.8 MILLION.FOR Q1 OF 2019, WORLDWIDE TALTZ REVENUE WAS $252.5 MILLION, AN INCREASE OF 72 PERCENT COMPARED WITH Q1 OF 2018.IN Q1 OF 2019, COMPANY RECOGNIZED ASSET IMPAIRMENT, RESTRUCTURING, AND OTHER SPECIAL CHARGES OF $423.9 MILLION.COMPANY ANTICIPATES 2019 REVENUE BETWEEN $22.0 BILLION AND $22.5 BILLION.2019 REVENUE GROWTH IS EXPECTED TO BE DRIVEN BY VOLUME FROM "KEY GROWTH" PRODUCTS INCLUDING TRULICITY, TALTZ, BASAGLAR, JARDIANCE.CHARGES IN QUARTER WERE PRIMARILY ASSOCIATED WITH ACCELERATED VESTING OF LOXO ONCOLOGY EMPLOYEE EQUITY AWARDS.Q1 EARNINGS PER SHARE VIEW $1.31, REVENUE VIEW $5.13 BILLION -- REFINITIV IBES DATA.  Full Article

Eli Lilly And Co posts Qtrly Non-GAAP EPS of $1.33
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Eli Lilly And Co ::LILLY REPORTS SOLID FIRST-QUARTER 2019 FINANCIAL RESULTS, UPDATES 2019 GUIDANCE TO REFLECT DISPOSITION OF ELANCO ANIMAL HEALTH.SEES FY 2019 EARNINGS PER SHARE $8.57 TO $8.67.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $5.60 TO $5.70.QTRLY EPS REPORTED $4.31.IN Q1 OF 2019, WORLDWIDE REVENUE WAS $5.092 BILLION, AN INCREASE OF 3 PERCENT COMPARED WITH Q1 OF 2018.2019 EPS GUIDANCE UPDATED TO BE IN RANGE OF $8.57 TO $8.67 ON A REPORTED BASIS AND $5.60 TO $5.70 ON A NON-GAAP BASIS.QTRLY EPS - NON-GAAP $1.33.FIRST-QUARTER 2019 WORLDWIDE TRULICITY REVENUE WAS $879.7 MILLION, AN INCREASE OF 30 PERCENT COMPARED WITH Q1 OF 2018.FIRST-QUARTER 2019 EPS ON A REPORTED BASIS INCLUDES GAIN ON SALE ASSOCIATED WITH DISPOSITION OF ELANCO ANIMAL HEALTH.FOR Q1 OF 2019, WORLDWIDE HUMALOG REVENUE DECREASED 8 PERCENT COMPARED WITH Q1 OF 2018, TO $730.8 MILLION.FOR Q1 OF 2019, WORLDWIDE TALTZ REVENUE WAS $252.5 MILLION, AN INCREASE OF 72 PERCENT COMPARED WITH Q1 OF 2018.IN Q1 OF 2019, COMPANY RECOGNIZED ASSET IMPAIRMENT, RESTRUCTURING, AND OTHER SPECIAL CHARGES OF $423.9 MILLION.COMPANY ANTICIPATES 2019 REVENUE BETWEEN $22.0 BILLION AND $22.5 BILLION.2019 REVENUE GROWTH IS EXPECTED TO BE DRIVEN BY VOLUME FROM "KEY GROWTH" PRODUCTS INCLUDING TRULICITY, TALTZ, BASAGLAR, JARDIANCE.CHARGES IN QUARTER WERE PRIMARILY ASSOCIATED WITH ACCELERATED VESTING OF LOXO ONCOLOGY EMPLOYEE EQUITY AWARDS.Q1 EARNINGS PER SHARE VIEW $1.31, REVENUE VIEW $5.13 BILLION -- REFINITIV IBES DATA.  Full Article

Deals of the day-Mergers and acquisitions

Aug 20 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday: